| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.577 | 0.024 | 0.614 | Antiobesity | 0.614 0.019 DBMET00371 | DBMET00371 | |
| 0.55 | 0.037 | 0.55 | Analgesic | 0.547 0.037 DBMET00371 | ||
| 0.482 | 0.035 | 0.502 | Toll-Like receptor agonist | 0.502 0.031 DBMET00371 | DBMET00371 | |
| 0.472 | 0.038 | 0.492 | Toll-Like receptor 7 agonist | 0.492 0.033 DBMET00371 | DBMET00371 | |
| 0.448 | 0.041 | 0.448 | Cholesterol antagonist | 0.404 0.049 DBMET00371 | ||
| 0.407 | 0.024 | 0.407 | Hypolipemic | 0.384 0.028 DBMET00371 | ||
| 0.387 | 0.023 | 0.387 | Anticonvulsant | 0.296 0.042 DBMET00371 | ||
| 0.369 | 0.035 | 0.369 | Antiamyloidogenic | 0.353 0.038 DBMET00371 | ||
| 0.395 | 0.094 | 0.433 | Cyclophilin D inhibitor | 0.433 0.074 DBMET00371 | DBMET00371 | |
| 0.406 | 0.107 | 0.406 | Caspase 9 stimulant | 0.281 0.216 DBMET00371 | ||
| 0.322 | 0.037 | 0.328 | Psychostimulant | 0.328 0.036 DBMET00371 | DBMET00371 | |
| 0.335 | 0.057 | 0.335 | Spasmolytic | 0.25 0.091 DBMET00371 | ||
| 0.305 | 0.048 | 0.305 | Potassium channel (Voltage-sensitive) blocker | 0.218 0.083 DBMET00371 | ||
| 0.302 | 0.046 | 0.302 | Potassium channel blocker | 0.205 0.089 DBMET00371 | ||
| 0.278 | 0.025 | 0.278 | Neurotrophic factor enhancer | 0.266 0.03 DBMET00371 | ||
| 0.298 | 0.057 | 0.298 | Cardiotonic | 0.218 0.104 DBMET00371 | ||
| 0.244 | 0.004 | 0.244 | Lanosterol 14 alpha demethylase inhibitor | 0.169 0.007 DBMET00371 | ||
| 0.352 | 0.113 | 0.352 | 5 Hydroxytryptamine release inhibitor | 0.306 0.158 DBMET00371 | ||
| 0.256 | 0.021 | 0.256 | Nav1.2 sodium channel blocker | 0.211 0.03 DBMET00371 | ||
| 0.245 | 0.026 | 0.254 | Antipruritic | 0.254 0.023 DBMET00371 | DBMET00371 | |
| 0.239 | 0.026 | 0.239 | Phospholipase A2 inhibitor | 0.225 0.031 DBMET00371 | ||
| 0.339 | 0.126 | 0.375 | Calcium channel L-type activator | 0.375 0.099 DBMET00371 | DBMET00371 | |
| 0.269 | 0.059 | 0.269 | HERG channel blocker | 0.174 0.107 DBMET00371 | ||
| 0.251 | 0.05 | 0.294 | Peptidyltransferase inhibitor | 0.294 0.027 DBMET00371 | DBMET00371 | |
| 0.242 | 0.046 | 0.242 | Non-steroidal antiinflammatory agent | 0.174 0.092 DBMET00371 | ||
| 0.213 | 0.024 | 0.213 | Cholesterol synthesis inhibitor | 0.121 0.064 DBMET00371 | ||
| 0.233 | 0.045 | 0.266 | Insulin sensitizer | 0.266 0.026 DBMET00371 | DBMET00371 | |
| 0.195 | 0.011 | 0.195 | Sphingomyelinase inhibitor | 0.156 0.022 DBMET00371 | ||
| 0.193 | 0.012 | 0.193 | 5 Hydroxytryptamine uptake inhibitor | 0.185 0.012 DBMET00371 | ||
| 0.204 | 0.023 | 0.204 | Nav1.3 sodium channel blocker | 0.196 0.026 DBMET00371 | ||
| 0.184 | 0.016 | 0.233 | Nav1.5 sodium channel blocker | 0.233 0.009 DBMET00371 | DBMET00371 | |
| 0.233 | 0.068 | 0.233 | Interleukin antagonist | 0.231 0.069 DBMET00371 | ||
| 0.162 | 0.003 | 0.217 | Glucagon receptor antagonist | 0.217 0.003 DBMET00371 | DBMET00371 | |
| 0.173 | 0.024 | 0.241 | Bronchodilator | 0.241 0.014 DBMET00371 | DBMET00371 | |
| 0.177 | 0.03 | 0.177 | Nav1.6 sodium channel blocker | 0.148 0.057 DBMET00371 | ||
| 0.261 | 0.12 | 0.261 | Transcription factor NF kappa B inhibitor | 0.256 0.123 DBMET00371 | ||
| 0.18 | 0.041 | 0.194 | Sodium channel blocker | 0.194 0.034 DBMET00371 | DBMET00371 | |
| 0.186 | 0.05 | 0.186 | Interleukin 6 antagonist | 0.172 0.062 DBMET00371 | ||
| 0.157 | 0.022 | 0.216 | NMDA receptor antagonist | 0.216 0.012 DBMET00371 | DBMET00371 | |
| 0.165 | 0.031 | 0.165 | Pregnane X receptor agonist | 0.14 0.073 DBMET00371 | ||
| 0.144 | 0.011 | 0.164 | Glutamate release inhibitor | 0.164 0.007 DBMET00371 | DBMET00371 | |
| 0.266 | 0.137 | 0.279 | Immunosuppressant | 0.279 0.128 DBMET00371 | DBMET00371 | |
| 0.173 | 0.043 | 0.173 | Calcium channel blocker | 0.156 0.054 DBMET00371 | ||
| 0.14 | 0.01 | 0.14 | Adrenaline uptake inhibitor | 0.14 0.01 DBMET00371 | ||
| 0.157 | 0.028 | 0.157 | Ca2+-transporting ATPase inhibitor | 0.147 0.049 DBMET00371 | ||
| 0.179 | 0.053 | 0.179 | Acetylcholine M1 receptor antagonist | 0.159 0.067 DBMET00371 | ||
| 0.13 | 0.01 | 0.171 | Sphingosine 1-phosphate receptor antagonist | 0.171 0.005 DBMET00371 | DBMET00371 | |
| 0.179 | 0.059 | 0.179 | ATPase inhibitor | 0.145 0.11 DBMET00371 | ||
| 0.155 | 0.035 | 0.192 | Sphingosine 1-phosphate receptor 2 antagonist | 0.192 0.01 DBMET00371 | DBMET00371 | |
| 0.13 | 0.014 | 0.13 | Calcium channel L-type blocker | 0.105 0.022 DBMET00371 | ||
| 0.255 | 0.141 | 0.263 | Calcium channel activator | 0.263 0.132 DBMET00371 | DBMET00371 | |
| 0.127 | 0.014 | 0.147 | Sphingosine 1-phosphate receptor 4 agonist | 0.147 0.009 DBMET00371 | DBMET00371 | |
| 0.117 | 0.006 | 0.154 | Sphingosine 1-phosphate receptor 1 antagonist | 0.154 0.004 DBMET00371 | DBMET00371 | |
| 0.159 | 0.049 | 0.165 | Sodium channel (voltage-gated) blocker | 0.165 0.045 DBMET00371 | DBMET00371 | |
| 0.116 | 0.009 | 0.116 | Glycine transporter inhibitor | 0.095 0.013 DBMET00371 | ||
| 0.215 | 0.11 | 0.45 | 5 Hydroxytryptamine release stimulant | 0.45 0.036 DBMET00371 | DBMET00371 | |
| 0.114 | 0.012 | 0.132 | Cannabinoid CB1 receptor antagonist | 0.132 0.009 DBMET00371 | DBMET00371 | |
| 0.123 | 0.022 | 0.123 | Interleukin 5 antagonist | 0.122 0.022 DBMET00371 | ||
| 0.182 | 0.085 | 0.182 | Anesthetic general | |||
| 0.103 | 0.008 | 0.103 | Exportin-1 inhibitor | 0.094 0.012 DBMET00371 | ||
| 0.117 | 0.022 | 0.131 | Cannabinoid receptor antagonist | 0.131 0.018 DBMET00371 | DBMET00371 | |
| 0.154 | 0.062 | 0.154 | Cell wall synthesis inhibitor | 0.153 0.063 DBMET00371 | ||
| 0.144 | 0.052 | 0.144 | Anesthetic local | 0.114 0.071 DBMET00371 | ||
| 0.105 | 0.017 | 0.105 | Dopamine uptake inhibitor | 0.088 0.022 DBMET00371 | ||
| 0.202 | 0.115 | 0.202 | Neuropeptide Y2 antagonist | 0.175 0.17 DBMET00371 | ||
| 0.128 | 0.043 | 0.128 | Nav1.1 sodium channel blocker | 0.092 0.077 DBMET00371 | ||
| 0.106 | 0.024 | 0.106 | Estrogen receptor alpha antagonist | 0.089 0.036 DBMET00371 | ||
| 0.106 | 0.027 | 0.106 | Glycine receptor antagonist | 0.074 0.066 DBMET00371 | ||
| 0.086 | 0.014 | 0.086 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.088 | 0.019 | 0.107 | Beta 3 adrenoreceptor antagonist | 0.107 0.013 DBMET00371 | DBMET00371 | |
| 0.07 | 0.005 | 0.07 | Liver X receptor beta antagonist | 0.052 0.008 DBMET00371 | ||
| 0.141 | 0.078 | 0.147 | Sphingosine 1-phosphate receptor 5 antagonist | 0.147 0.067 DBMET00371 | DBMET00371 | |
| 0.129 | 0.066 | 0.153 | Glutamate receptor antagonist | 0.153 0.049 DBMET00371 | DBMET00371 | |
| 0.124 | 0.063 | 0.124 | Acetylcholine muscarinic antagonist | 0.109 0.08 DBMET00371 | ||
| 0.107 | 0.045 | 0.107 | Alcohol dehydrogenase inhibitor | 0.088 0.066 DBMET00371 | ||
| 0.124 | 0.065 | 0.138 | Adenylate cyclase inhibitor | 0.138 0.054 DBMET00371 | DBMET00371 | |
| 0.068 | 0.01 | 0.068 | Glycine transporter 1 inhibitor | 0.051 0.015 DBMET00371 | ||
| 0.06 | 0.004 | 0.06 | Ceramide glucosyltransferase inhibitor | 0.055 0.005 DBMET00371 | ||
| 0.219 | 0.165 | 0.219 | Vasodilator, coronary | |||
| 0.075 | 0.022 | 0.075 | Corticotropin releasing factor 2 receptor antagonist | 0.069 0.03 DBMET00371 | ||
| 0.058 | 0.005 | 0.058 | Cholesterol ester transfer protein antagonist | 0.056 0.005 DBMET00371 | ||
| 0.089 | 0.039 | 0.089 | T cell inhibitor | 0.086 0.048 DBMET00371 | ||
| 0.127 | 0.076 | 0.135 | Interleukin 4 antagonist | 0.135 0.065 DBMET00371 | DBMET00371 | |
| 0.237 | 0.189 | 0.26 | Antibacterial | 0.26 0.168 DBMET00371 | DBMET00371 | |
| 0.061 | 0.013 | 0.061 | Benzodiazepine antagonist | 0.045 0.04 DBMET00371 | ||
| 0.065 | 0.017 | 0.065 | NMDA receptor subunit 3B antagonist | 0.056 0.021 DBMET00371 | ||
| 0.08 | 0.033 | 0.08 | Peroxisome proliferator-activated receptor gamma antagonist | 0.076 0.04 DBMET00371 | ||
| 0.114 | 0.067 | 0.114 | Estrogen antagonist | 0.105 0.086 DBMET00371 | ||
| 0.061 | 0.016 | 0.081 | Sphingosine 1-phosphate receptor agonist | 0.081 0.008 DBMET00371 | DBMET00371 | |
| 0.062 | 0.016 | 0.062 | NMDA receptor subunit 3A antagonist | 0.06 0.017 DBMET00371 | ||
| 0.073 | 0.029 | 0.073 | Acetylcholine M5 receptor antagonist | 0.072 0.029 DBMET00371 | ||
| 0.057 | 0.014 | 0.068 | Sphingosine 1-phosphate receptor 1 agonist | 0.068 0.009 DBMET00371 | DBMET00371 | |
| 0.107 | 0.067 | 0.109 | Nav1.4 sodium channel blocker | 0.109 0.063 DBMET00371 | DBMET00371 | |
| 0.107 | 0.068 | 0.108 | Electron transport complex I inhibitor | 0.108 0.066 DBMET00371 | DBMET00371 | |
| 0.073 | 0.034 | 0.1 | Beta adrenoreceptor antagonist | 0.1 0.016 DBMET00371 | DBMET00371 | |
| 0.067 | 0.029 | 0.098 | Sphingosine 1-phosphate receptor 3 antagonist | 0.098 0.009 DBMET00371 | DBMET00371 | |
| 0.107 | 0.07 | 0.107 | Interleukin 2 antagonist | |||
| 0.076 | 0.038 | 0.076 | Potassium channel large-conductance Ca-activated activator | 0.066 0.049 DBMET00371 | ||
| 0.062 | 0.026 | 0.062 | Pregnane X receptor antagonist | 0.058 0.035 DBMET00371 | ||
| 0.097 | 0.062 | 0.097 | Electrolyte absorption antagonist | |||
| 0.059 | 0.025 | 0.062 | Dopamine transporter inhibitor | 0.062 0.024 DBMET00371 | DBMET00371 | |
| 0.091 | 0.058 | 0.11 | Aminoacyl-tRNA synthetase inhibitor | 0.11 0.036 DBMET00371 | DBMET00371 | |
| 0.208 | 0.176 | 0.247 | Interleukin 2 agonist | 0.247 0.122 DBMET00371 | DBMET00371 | |
| 0.114 | 0.084 | 0.146 | Sphingosine 1-phosphate receptor 4 antagonist | 0.146 0.037 DBMET00371 | DBMET00371 | |
| 0.102 | 0.073 | 0.102 | Alpha 2b adrenoreceptor antagonist | 0.095 0.079 DBMET00371 | ||
| 0.091 | 0.062 | 0.162 | Antiadrenergic | 0.162 0.033 DBMET00371 | DBMET00371 | |
| 0.087 | 0.058 | 0.087 | Androgen antagonist | |||
| 0.067 | 0.039 | 0.07 | DNA gyrase inhibitor | 0.07 0.036 DBMET00371 | DBMET00371 | |
| 0.074 | 0.047 | 0.074 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.04 | 0.014 | 0.04 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.087 | 0.063 | 0.16 | Adrenaline antagonist | 0.16 0.032 DBMET00371 | DBMET00371 | |
| 0.053 | 0.03 | 0.053 | Peroxisome proliferator-activated receptor alpha agonist | |||
| 0.037 | 0.014 | 0.048 | Lysophosphatidic acid 2 receptor antagonist | 0.048 0.009 DBMET00371 | DBMET00371 | |
| 0.035 | 0.013 | 0.035 | Liver X receptor alpha antagonist | 0.031 0.017 DBMET00371 | ||
| 0.061 | 0.04 | 0.061 | Prostaglandin EP2 antagonist | 0.059 0.042 DBMET00371 | ||
| 0.06 | 0.041 | 0.06 | Bcl-xL inhibitor | |||
| 0.051 | 0.033 | 0.051 | Potassium channel (Inward rectifier) blocker | |||
| 0.031 | 0.012 | 0.031 | 1,3-Beta-glucan synthase inhibitor | 0.031 0.012 DBMET00371 | ||
| 0.19 | 0.172 | 0.193 | 5 Hydroxytryptamine uptake stimulant | 0.193 0.166 DBMET00371 | DBMET00371 | |
| 0.034 | 0.017 | 0.034 | Prostaglandin D2 agonist | 0.032 0.02 DBMET00371 | ||
| 0.025 | 0.008 | 0.025 | Prostaglandin EP4 agonist | |||
| 0.093 | 0.077 | 0.142 | Carbonic anhydrase XV inhibitor | 0.142 0.034 DBMET00371 | DBMET00371 | |
| 0.034 | 0.018 | 0.034 | Liver X receptor antagonist | 0.029 0.024 DBMET00371 | ||
| 0.061 | 0.046 | 0.07 | Beta 2 adrenoreceptor agonist | 0.07 0.019 DBMET00371 | DBMET00371 | |
| 0.032 | 0.019 | 0.032 | Prostaglandin agonist | |||
| 0.071 | 0.059 | 0.075 | Potassium channel (Tandem pore domain) blocker | 0.075 0.049 DBMET00371 | DBMET00371 | |
| 0.025 | 0.014 | 0.025 | Prostaglandin E2 agonist | |||
| 0.057 | 0.045 | 0.057 | Acetylcholine M3 receptor antagonist | 0.057 0.045 DBMET00371 | ||
| 0.025 | 0.015 | 0.025 | Prostaglandin EP2 agonist | 0.019 0.018 DBMET00371 | ||
| 0.057 | 0.047 | 0.057 | Dopamine D3 antagonist | 0.055 0.05 DBMET00371 | ||
| 0.059 | 0.049 | 0.08 | NMDA receptor agonist | 0.08 0.029 DBMET00371 | DBMET00371 | |
| 0.053 | 0.043 | 0.081 | Beta 1 adrenoreceptor antagonist | 0.081 0.018 DBMET00371 | DBMET00371 | |
| 0.097 | 0.089 | 0.097 | Calcium channel (voltage-sensitive) blocker | |||
| 0.09 | 0.083 | 0.09 | Estrogen receptor beta antagonist | |||
| 0.039 | 0.032 | 0.039 | Liver X receptor alpha agonist | |||
| 0.032 | 0.025 | 0.032 | Liver X receptor beta agonist | |||
| 0.022 | 0.016 | 0.022 | Corticotropin releasing factor 1 receptor antagonist | |||
| 0.051 | 0.046 | 0.058 | Sphingosine kinase 2 inhibitor | 0.058 0.033 DBMET00371 | DBMET00371 | |
| 0.04 | 0.035 | 0.04 | Liver X receptor agonist | |||
| 0.038 | 0.033 | 0.038 | Neurokinin 1 antagonist | |||
| 0.015 | 0.011 | 0.017 | Calcium-sensing receptor antagonist | 0.017 0.01 DBMET00371 | DBMET00371 | |
| 0.046 | 0.043 | 0.046 | 5 Hydroxytryptamine 2 agonist | 0.045 0.044 DBMET00371 | ||
| 0.054 | 0.051 | 0.054 | Androgen agonist | |||
| 0.089 | 0.087 | 0.11 | AMP-activated protein kinase stimulant | 0.11 0.059 DBMET00371 | DBMET00371 | |
| 0.044 | 0.041 | 0.052 | Cannabinoid CB2 receptor antagonist | 0.052 0.036 DBMET00371 | DBMET00371 | |
| 0.026 | 0.023 | 0.03 | LFA antagonist | 0.03 0.016 DBMET00371 | DBMET00371 | |
| 0.083 | 0.081 | 0.083 | ABCA1 expression enhancer | |||
| 0.023 | 0.021 | 0.025 | Prostaglandin EP4 antagonist | 0.025 0.019 DBMET00371 | DBMET00371 | |
| 0.037 | 0.036 | 0.038 | Phenylethanolamine N methyltransferase inhibitor | 0.038 0.034 DBMET00371 | DBMET00371 | |
| 0.035 | 0.034 | 0.035 | Substance P antagonist | |||
| 0.045 | 0.044 | 0.069 | Beta 2 adrenoreceptor antagonist | 0.069 0.017 DBMET00371 | DBMET00371 | |
| 0.068 | 0.076 | 0.122 | Adrenaline agonist | 0.122 0.025 DBMET00371 | DBMET00371 | |
| 0.029 | 0.041 | 0.036 | Kainate receptor antagonist | 0.036 0.033 DBMET00371 | DBMET00371 | |
| 0.034 | 0.048 | 0.038 | Glucagon-like peptide 1 receptor antagonist | 0.038 0.032 DBMET00371 | DBMET00371 | |
| 0.036 | 0.052 | 0.076 | NMDA 2A receptor antagonist | 0.076 0.021 DBMET00371 | DBMET00371 | |
| 0.029 | 0.054 | 0.043 | Glycine transporter 2 inhibitor | 0.043 0.035 DBMET00371 | DBMET00371 | |
| 0.044 | 0.069 | 0.057 | TRPA1 antagonist | 0.057 0.048 DBMET00371 | DBMET00371 | |
| 0.062 | 0.089 | 0.087 | Ornithine decarboxylase inhibitor | 0.087 0.059 DBMET00371 | DBMET00371 | |
| 0.044 | 0.072 | 0.056 | Botulinum neurotoxin type A inhibitor | 0.056 0.045 DBMET00371 | DBMET00371 | |
| 0.038 | 0.07 | 0.047 | Beta adrenoreceptor agonist | 0.047 0.026 DBMET00371 | DBMET00371 | |
| 0.036 | 0.075 | 0.046 | Potassium channel (ATP-sensitive) activator | 0.046 0.039 DBMET00371 | DBMET00371 | |
| 0.037 | 0.078 | 0.048 | Potassium channel (Inward rectifier) activator | 0.048 0.04 DBMET00371 | DBMET00371 | |
| 0.059 | 0.107 | 0.073 | Vanilloid 4 agonist | 0.073 0.057 DBMET00371 | DBMET00371 | |
| 0.032 | 0.108 | 0.069 | NMDA 2 receptor antagonist | 0.069 0.052 DBMET00371 | DBMET00371 | |
| 0.025 | 0.118 | 0.042 | Histamine H1 receptor agonist | 0.042 0.034 DBMET00371 | DBMET00371 | |
| 0.045 | 0.168 | 0.076 | Inducible nitric-oxide synthase inhibitor | 0.076 0.07 DBMET00371 | DBMET00371 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |